{"id":"pyrotinib-trastuzumab-docetaxel","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1201585","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pyrotinib works by inhibiting the tyrosine kinase activity of the HER2/neu receptor, which is overexpressed in certain types of cancer. Trastuzumab binds to the HER2 protein on the surface of cancer cells, marking them for destruction by the immune system. Docetaxel interferes with the normal function of microtubules in cells, which are necessary for cell division and growth.","oneSentence":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while Trastuzumab is a monoclonal antibody targeting the HER2 protein, and Docetaxel is a taxane inhibitor of microtubule assembly.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:44.774Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic breast cancer with HER2 overexpression"},{"name":"Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression"}]},"trialDetails":[{"nctId":"NCT07335081","phase":"PHASE2","title":"ctDNA in HER2+ EBC Neoadjuvant Treatment","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-02-01","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT07393425","phase":"PHASE2","title":"Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-02","conditions":"HER2 + Breast Cancer","enrollment":50},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT07239271","phase":"PHASE3","title":"A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-16","conditions":"Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy","enrollment":2000},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT03588091","phase":"PHASE3","title":"Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-07-24","conditions":"HER2-positive Breast Cancer","enrollment":355},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT06770296","phase":"PHASE1","title":"The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-01","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT05426486","phase":"PHASE2, PHASE3","title":"A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Caigang Liu","startDate":"2022-05-23","conditions":"HER2-positive Breast Cancer","enrollment":136},{"nctId":"NCT06278870","phase":"PHASE3","title":"Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-09-06","conditions":"HER2-positive Metastatic Breast Cancer, First-line Treatment","enrollment":312},{"nctId":"NCT06254690","phase":"PHASE2","title":"The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT04367090","phase":"PHASE1","title":"Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-05-28","conditions":"Metastatic Breast Cancer","enrollment":97},{"nctId":"NCT05638594","phase":"PHASE2","title":"Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2022-12-20","conditions":"Breast Cancer","enrollment":236},{"nctId":"NCT05430347","phase":"PHASE2","title":"Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-04-15","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT03735966","phase":"PHASE2","title":"Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2018-11-20","conditions":"HER2 Positive Breast Cancer","enrollment":75},{"nctId":"NCT03863223","phase":"PHASE3","title":"A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-04-22","conditions":"Metastatic Breast Cancer","enrollment":590},{"nctId":"NCT04769050","phase":"","title":"Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-18","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT04929548","phase":"PHASE4","title":"Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP","status":"NOT_YET_RECRUITING","sponsor":"Wuhan University","startDate":"2022-01-05","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT04717531","phase":"PHASE2","title":"Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-06-03","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT04760431","phase":"PHASE2","title":"TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-10-01","conditions":"HER2-positive Breast Cancer, Brain Metastases","enrollment":120},{"nctId":"NCT03756064","phase":"NA","title":"Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-01","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":100},{"nctId":"NCT03847818","phase":"NA","title":"Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-03-01","conditions":"HER2-positive Breast Cancer","enrollment":268}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pyrotinib, Trastuzumab, Docetaxel","genericName":"Pyrotinib, Trastuzumab, Docetaxel","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pyrotinib is a tyrosine kinase inhibitor that targets the HER2/neu receptor, while Trastuzumab is a monoclonal antibody targeting the HER2 protein, and Docetaxel is a taxane inhibitor of microtubule assembly. Used for Advanced or metastatic breast cancer with HER2 overexpression, Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}